Has Susan Smiga received payments from drug or device companies?

Yes. Drug and device makers reported $4,810 in general payments to Susan Smiga across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Smiga did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Smiga come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Smiga

Psychiatry · Sacramento, CANPI 1740202209

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,001 of the $4,810 with a category attached, or 83.2%. 3 manufacturers reported payments, led by Livanova USA, Inc. at 44.4% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,810in general payments, 2019–2025

Across 30 payments — averaging $160.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Livanova USA, Inc.$2K
Merck$1K
Biohaven Pharmaceutical Holding Company Ltd.$1K

$1,710,712in research payments, 2019–2025

Across 206 payments — averaging $8304.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Otsuka Pharmaceutical Development & Commercialization, Inc.$751K
Pfizer$431K
Livanova USA, Inc.$218K
AbbVie$200K
Sage Therapeutics, LLC$82K
Supernus Pharmaceuticals, Inc.$17K
plus $12K from 2 others

What the payments were for

Travel & lodging$4,00183%
Food & beverage$80917%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Livanova USA, Inc.	9	$2,135
Merck	11	$1,421
Biohaven Pharmaceutical Holding Company Ltd.	10	$1,254

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VNS Therapy$1,901

How this compares

$4,810 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Divalproex Sodium ErDivalproex Sodium	16	$1,259
Olanzapine	34	$734
Quetiapine Fumarate	16	$595
Trazodone Hcl	27	$446
Lamotrigine	12	$122
Risperidone	16	$120
Sertraline Hcl	17	$113
Benztropine Mesylate	13	$96

Paid to pharmacies, not to this prescriber.

Other psychiatry in Sacramento

David SmithSacramento$588K
Jacob AdamsSacramento$419K
Robert McCarronSacramento$136K
Gustavo AlvaOrange$5.8M
John KooSan Francisco$3M
Jason KelloggIrvine$2.7M
Jonathan MeyerSan Diego$2.3M
Charles Tuan-Tu NguyenIrvine$2.1M
Manoj WaikarLos Gatos$1.9M
Gerald MaguireSan Juan Capistraco$1.8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →